Tech Strength Drives Rally… And Eli Lilly Beats Out The Competition 12/4/24
Big tech taking the lead, and driving the S&P 500 and Nasdaq to fresh record highs. How semis, software, and other sections of the tech trade can fuel your portfolio. Plus Fast Money’s Obesity Week coverage continues. Eli Lilly’s Chief Scientific Officer breaks down how the company’s obesity drug Zepbound performed in its first head-to-head clinical trial against Novo’s Wegovy, and what the results could mean for the weight loss drug wars. Fast Money Disclaimer
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Big tech taking the lead, and driving the S&P 500 and Nasdaq to fresh record highs. How semis, software, and other sections of the tech trade can fuel your portfolio. Plus Fast Money’s Obesity Week coverage continues. Eli Lilly’s Chief Scientific Officer breaks down how the company’s obesity drug Zepbound performed in its first head-to-head clinical trial against Novo’s Wegovy, and what the results could mean for the weight loss drug wars.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.